source
- Beyond GLP-1s: Companies eye new obesity drug mechanisms as efficacy plateausThe obesity drug market continues to expand, with GLP-1 therapies growing from about $5.5 billion in 2023 to over $55 billion projected for 2033. These agents are used for weight loss, diabetes and…
- UniQure submits FDA and UK applications for first Huntington’s disease gene therapyUniQure has filed a biologics license application (BLA) with the U.S. FDA and a separate submission with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its experimental gene…